دورية أكاديمية
أعرض في EDS

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

التفاصيل البيبلوغرافية
العنوان: Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.
المؤلفون: Rodrigueza WV; ProNAi Therapeutics, Inc., Plymouth, MI, USA, wrodrigueza@pronai.com., Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A
المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2014 Jul; Vol. 74 (1), pp. 151-66. Date of Electronic Publication: 2014 May 16.
نوع المنشور: Comparative Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin, New York, Springer International.
مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , DNA, Antisense/*therapeutic use , DNA, Single-Stranded/*therapeutic use , Gene Silencing/*drug effects , Neoplasms/*drug therapy , Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors, 5' Flanking Region/drug effects ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/metabolism ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; DNA, Antisense/administration & dosage ; DNA, Antisense/pharmacokinetics ; DNA, Antisense/pharmacology ; DNA, Single-Stranded/administration & dosage ; DNA, Single-Stranded/pharmacokinetics ; DNA, Single-Stranded/pharmacology ; Drug Compounding ; Drug Stability ; Female ; Liposomes ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mice, SCID ; Neoplasms/blood ; Oligodeoxyribonucleotides/chemistry ; Oligodeoxyribonucleotides/pharmacokinetics ; Oligodeoxyribonucleotides/pharmacology ; Oligodeoxyribonucleotides/therapeutic use ; Pharmaceutical Vehicles ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Random Allocation ; Xenograft Model Antitumor Assays
مستخلص: PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the BCL-2 gene. Exposure of tumor cells to PNT100 results in suppression of proliferation and cell death by a process called DNA interference. PNT2258 is PNT100 that is encapsulated in protective amphoteric liposomes developed to efficiently encapsulate the PNT100 oligonucleotide, provide enhanced serum stability, optimized pharmacokinetic properties and antitumor activity of the nanoparticle both in vivo and in vitro. PNT2258 demonstrates broad antitumor activity against BCL-2-driven WSU-DLCL2 lymphoma, highly resistant A375 melanoma, PC-3 prostate, and Daudi-Burkitt's lymphoma xenografts. The sequence specificity of PNT100 was demonstrated against three control sequences (scrambled, mismatched, and reverse complement) all encapsulated in a lipid formulation with identical particle characteristics, and control sequences did not demonstrate antiproliferative activity in vivo or in vitro. PNT2258 is currently undergoing clinical testing to evaluate safety and antitumor activity in patients with recurrent or refractory non-Hodgkin's lymphoma and additional studies are planned.
References: Mol Ther. 2010 Jul;18(7):1357-64. (PMID: 20461061)
Nat Chem Biol. 2005 Sep;1(4):216-22. (PMID: 16408038)
J Clin Oncol. 2012 Sep 1;30(25):3127-35. (PMID: 22649144)
BMC Mol Biol. 2011 Aug 05;12:33. (PMID: 21816114)
Chem Biol. 2012 Aug 24;19(8):937-54. (PMID: 22921062)
Eur J Pharm Biopharm. 2002 Sep;54(2):213-9. (PMID: 12191694)
Clin Cancer Res. 2011 Dec 15;17(24):7785-95. (PMID: 21933893)
Nat Methods. 2006 Jul;3(7):511-8. (PMID: 16791208)
Biochim Biophys Acta. 1993 Nov 21;1153(1):9-19. (PMID: 8241255)
Silence. 2010 Jul 08;1(1):14. (PMID: 20615220)
Epigenetics. 2011 Feb;6(2):147-52. (PMID: 20935486)
Mol Cell Biol. 1995 Jul;15(7):3840-7. (PMID: 7791791)
J Mol Med (Berl). 2002 Oct;80(10):620-8. (PMID: 12395146)
Jpn J Cancer Res. 2001 Sep;92(9):933-40. (PMID: 11572760)
Mol Cancer Ther. 2002 Mar;1(5):347-55. (PMID: 12489851)
EMBO J. 1988 Jan;7(1):123-31. (PMID: 2834197)
Cancer Chemother Pharmacol. 2014 Feb;73(2):363-71. (PMID: 24297683)
Pure Appl Chem. 2010 Jan 1;82(8):1609-1621. (PMID: 21796223)
J Biol Chem. 2011 Dec 23;286(51):44095-44103. (PMID: 22049078)
Arthritis Rheum. 2009 Apr;60(4):994-1005. (PMID: 19333921)
Cancer Chemother Pharmacol. 2005 Jul;56(1):46-54. (PMID: 15791457)
J Clin Oncol. 2012 Oct 1;30(28):3460-7. (PMID: 22665537)
Genes Dev. 2011 May 15;25(10):1010-22. (PMID: 21576262)
Oncogene. 2002 May 30;21(24):3898-908. (PMID: 12032828)
J Drug Target. 2002 Nov;10(7):539-48. (PMID: 12683721)
J Control Release. 2013 Feb 10;165(3):163-72. (PMID: 23178664)
Nat Rev Drug Discov. 2011 Apr;10(4):261-75. (PMID: 21455236)
EMBO Mol Med. 2012 Mar;4(3):143-59. (PMID: 22351564)
Nature. 2004 Sep 9;431(7005):211-7. (PMID: 15311210)
Expert Opin Biol Ther. 2001 Nov;1(6):923-47. (PMID: 11728226)
Expert Opin Ther Targets. 2013 Jan;17(1):61-75. (PMID: 23173842)
Ann Oncol. 2006 Sep;17 Suppl 10:x315-24. (PMID: 17018746)
J Immunol. 1991 Jun 15;146(12):4234-41. (PMID: 2040798)
Genes Cancer. 2010 Jun;1(6):641-649. (PMID: 21113409)
Nature. 2012 Sep 6;489(7414):75-82. (PMID: 22955617)
Nat Rev Drug Discov. 2012 Jan 20;11(2):125-40. (PMID: 22262036)
Biophys J. 2011 May 18;100(10):2412-21. (PMID: 21575575)
Clin Cancer Res. 1998 Jun;4(6):1393-403. (PMID: 9626455)
Oncogene. 2008 Dec 4;27(53):6720-8. (PMID: 18695675)
Cancer Res. 1994 Jun 15;54(12):3131-5. (PMID: 8205530)
ACS Nano. 2009 Jan 27;3(1):16-20. (PMID: 19206243)
Clin Cancer Res. 2004 Nov 1;10(21):7244-51. (PMID: 15534098)
J Cell Biol. 1994 Jan;124(1-2):1-6. (PMID: 8294493)
Annu Rev Genomics Hum Genet. 2006;7:29-59. (PMID: 16719718)
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1329-31. (PMID: 3547408)
Mol Cell Biol. 1993 Jun;13(6):3686-97. (PMID: 8388542)
Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2132-9. (PMID: 9351382)
J Liposome Res. 2002;12(3):259-70. (PMID: 12604030)
Cancer Res. 1984 Feb;44(2):717-26. (PMID: 6692374)
Cancer Genet Cytogenet. 1993 Oct 1;70(1):62-7. (PMID: 8221615)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (DNA, Antisense)
0 (DNA, Single-Stranded)
0 (Liposomes)
0 (Oligodeoxyribonucleotides)
0 (PNT100)
0 (Pharmaceutical Vehicles)
0 (Proto-Oncogene Proteins c-bcl-2)
تواريخ الأحداث: Date Created: 20140517 Date Completed: 20140926 Latest Revision: 20211021
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4077254
DOI: 10.1007/s00280-014-2476-y
PMID: 24832107
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0843
DOI:10.1007/s00280-014-2476-y